title: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
abstract: The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). This was a 28-week, double-blind, parallel, randomized controlled trial of memantine 20 mg daily versus placebo which was conducted in 54 centres in the UK. Memantine is a uncompetitive, moderate affinity N-methyl-D-aspartate receptor antagonist. Patients with a diagnosis of probable VaD and Mini Mental State Examination total scores between 10 and 22 were eligible for inclusion. Primary efficacy parameters were the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and the Clinical Global Impression of Change (CGI-C). A total of 579 patients were randomized and 548 patients with at least one post-baseline efficacy assessment qualified for the intent-to-treat analysis. At endpoint, memantine was shown to improve cognition relative to placebo in VaD: the change of ADAS-cog from baseline differed by a mean of -1.75 points (95% confidence intervals -3.023 to -0.49) and a median of 2 points between the two groups, while CGI-C ratings showed no significant differences between treatment groups. A total of 77% of all memantine-treated patients experienced adverse event, versus 75% of the placebo-treated patients, dizziness being the most frequent adverse event (11% versus 8%, respectively). Memantine was well tolerated and safe.
authors.affiliation: Bristol University, Department of Care of the Elderly, Frenchay Hospital, Bristol, UK.
authors.forename: G
authors.initials: G
authors.lastname: Wilcock
authors.forename: H J
authors.initials: HJ
authors.lastname: Möbius
authors.forename: A
authors.initials: A
authors.lastname: Stöffler
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000494:pharmacology*; D003071:Cognition; D015140:Dementia, Vascular / Q000188:drug therapy* / Q000473:pathology; D004244:Dizziness / Q000139:chemically induced; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008559:Memantine / Q000009:adverse effects / Q000494:pharmacology*; D008609:Mental Status Schedule; D010919:Placebos; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D010919:Placebos; D008559:Memantine